Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox)

Ruth L. Quispe, Michael L. Jaramillo, Frank Torres-Huaco, Cesar Bonilla, Jacqueline Isasi, Clara Guerra-Duarte, Carlos Chávez-Olórtegui

Producción científica: Artículo CientíficoArtículo originalrevisión exhaustiva

3 Citas (Scopus)

Resumen

Loxoscelism is a serious public health problem in Peru, with approximately 2500 accidents reported per year. To envision alternatives to cope with this health problem, the neutralizing humoral immune response against the lethal effects of Peruvian spider Loxosceles laeta venom was evaluated in a mouse model by immunization with a non-toxic multiepitopic protein (rMEPLox). This immunogen contains epitopes from an astacin-like metalloprotease, a hyaluronidase and a sphingomyelinase-D from Loxosceles intermedia and from SMase-I from L. laeta venoms. In vivo protection assays showed that five out of six mice immunized with rMEPLox (after six injections) resisted to 1.4 LD50 of L. laeta venom, whereas only two animals from a control group survived. The present results indicates that this multiepitopic protein can be a promising candidate for anti-loxoscelic antivenom production and experimental vaccination approaches.

Idioma originalInglés estadounidense
Páginas (desde-hasta)1-5
-5
PublicaciónToxicon
Volumen215
DOI
EstadoIndizado - ago. 2022

Nota bibliográfica

Publisher Copyright:
© 2022 Elsevier Ltd

Huella

Profundice en los temas de investigación de 'Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox)'. En conjunto forman una huella única.

Citar esto